Search / Trial NCT00001029

A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of September 11, 2024

Completed

Keywords

Zalcitabine Didanosine Drug Therapy, Combination Acquired Immunodeficiency Syndrome Zidovudine

Description

Combining two nucleoside drugs has the theoretical advantage of optimal protection against the evolution of resistant strains of HIV. However, one major problem with combination nucleoside therapy in patients with advanced disease is the increased toxicity resulting from such therapy. One approach to minimize toxicity while perhaps retaining some of the benefits of combination therapy is to alternate the two drugs. Patients are randomized to one of three treatment arms: AZT plus ddI, AZT plus ddC, and AZT alone alternating monthly with ddI. Half of the patients receiving AZT alternating mo...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Required:
  • * PCP prophylaxis.
  • Allowed:
  • * Erythropoietin.
  • * Prophylaxis for MAI or fungal infections.
  • * Antibiotics.
  • * Over-the-counter, alternative, or regularly prescribed drugs.
  • * Steroids, if for \< 21 days.
  • Concurrent Treatment:
  • Allowed:
  • * Radiation therapy for cutaneous Kaposi's sarcoma.
  • Patients must have:
  • * HIV infection.
  • * CD4 count \<= 50 cells/mm3.
  • * Prior nucleoside monotherapy for at least 6 months.
  • * Life expectancy of at least 6 months.
  • Prior Medication: Required:
  • * Nucleoside monotherapy for at least 6 months. Active alcohol or drug abuse.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following symptoms or conditions are excluded:
  • * Severe peripheral neuropathy.
  • * Psychological or emotional problems sufficient to prevent study compliance.
  • Concurrent Medication:
  • Excluded:
  • * Systemic chemotherapy for malignancy.
  • * Acute or induction therapy for opportunistic infection.
  • Patients with the following prior conditions are excluded:
  • * History of acute or chronic pancreatitis.
  • * Grade 3 or greater toxicity to AZT, ddI, or ddC on two or more occasions.
  • Prior Medication:
  • Excluded:
  • * Non-study nucleosides or biologic response modifiers within 7 days prior to study entry.
  • * Acute therapy for opportunistic process within 14 days prior to study entry.
  • * Acute systemic therapy for other medical conditions within 14 days prior to study entry.

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Los Angeles, California, United States

Palo Alto, California, United States

San Diego, California, United States

San Francisco, California, United States

San Jose, California, United States

San Mateo, California, United States

Torrance, California, United States

Aurora, Colorado, United States

Miami, Florida, United States

Honolulu, Hawaii, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

Indianapolis, Indiana, United States

Indianapolis, Indiana, United States

Iowa City, Iowa, United States

Boston, Massachusetts, United States

Boston, Massachusetts, United States

Boston, Massachusetts, United States

Minneapolis, Minnesota, United States

Minneapolis, Minnesota, United States

Saint Louis, Missouri, United States

Saint Louis, Missouri, United States

Omaha, Nebraska, United States

New York, New York, United States

New York, New York, United States

New York, New York, United States

New York, New York, United States

Rochester, New York, United States

Chapel Hill, North Carolina, United States

Cincinnati, Ohio, United States

Cleveland, Ohio, United States

Columbus, Ohio, United States

Philadelphia, Pennsylvania, United States

Seattle, Washington, United States

San Juan, , Puerto Rico

Mbeya, , Tanzania

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0